Viagra vs Alprostadil (Caverject/MUSE): Cost and Access Head-to-Head

How the Two Drugs Work Differently

Sildenafil and alprostadil treat erectile dysfunction through entirely separate mechanisms, and that mechanistic split drives most of their cost and access differences. Sildenafil is an oral PDE5 inhibitor that enhances nitric oxide signaling. Alprostadil is a synthetic prostaglandin E1 that acts directly on cavernosal smooth muscle, delivered by penile injection (Caverject) or urethral pellet (MUSE).

The Goldstein et al. key trial (N=532) published in the New England Journal of Medicine established sildenafil as the first oral treatment for ED, with 82% of men on the 100 mg dose reporting improved erections versus 24% on placebo [1]. Two years earlier, the Linet et al. trial (N=296) demonstrated that alprostadil intracavernosal injection produced a dose-response effect with approximately 70% of men achieving erections sufficient for intercourse [2], including men who had failed other therapies.

No large randomized head-to-head trial has directly compared sildenafil to alprostadil. Cross-trial comparisons suggest similar efficacy ceilings, but the populations differ. Sildenafil trials enrolled broad ED populations. Alprostadil data skews toward men with more severe vascular or neurogenic ED, including post-prostatectomy patients who often do not respond to oral PDE5 inhibitors. A 2003 meta-analysis in the British Journal of Urology International estimated that intracavernosal alprostadil produced successful intercourse in 71 to 81% of attempts across pooled studies [3], a range that overlaps with sildenafil response rates in less severe populations.

Cost Per Dose: Sildenafil vs Alprostadil

Generic sildenafil is one of the least expensive branded-to-generic conversions in urology, while alprostadil remains comparatively costly regardless of formulation. This gap shapes prescribing patterns and out-of-pocket burden more than any efficacy difference.

Since Pfizer's U.S. patent on Viagra expired in 2017, generic sildenafil 20 mg, 50 mg, and 100 mg tablets have entered the market from dozens of manufacturers. Cash prices at major retail chains (CVS, Walgreens, Walmart) with discount coupons range from $1 to $8 per tablet for the 100 mg dose [4], which many men split into two 50 mg doses, effectively halving the per-use cost. Brand Viagra, still available, lists at $70 to $85 per tablet. Few patients pay that price.

Alprostadil presents a different picture. Caverject Impulse (Pfizer) runs $30 to $75 per injection depending on dose (10 mcg or 20 mcg) and pharmacy. MUSE pellets (Meda Pharmaceuticals) cost $25 to $55 each. Generic alprostadil for injection exists, but only a small number of manufacturers produce it, and many retail pharmacies do not stock it routinely. Compounding pharmacies can prepare alprostadil in trimix formulations (alprostadil + papaverine + phentolamine) at lower per-injection cost ($3 to $10 per dose), though this route involves non-FDA-approved combinations and variable insurance acceptance.

The annual cost difference is significant. A man using sildenafil twice weekly (104 doses per year) at $4 per dose spends roughly $416 annually. The same frequency with Caverject at $50 per dose totals $5,200. That order-of-magnitude gap is the single largest factor in first-line prescribing.

Insurance Coverage and Prior Authorization

Most commercial insurers and Medicare Part D plans cover generic sildenafil, though quantity limits and prior authorization requirements vary. Alprostadil coverage is less predictable and typically requires documented PDE5 inhibitor failure before approval.

Generic sildenafil sits on Tier 1 or Tier 2 of most formularies. Common restrictions include a cap of 6 to 12 tablets per month and a requirement that the prescribing indication is erectile dysfunction (not pulmonary arterial hypertension dosing at 20 mg three times daily, which has its own coverage pathway). The American Urological Association (AUA) 2018 guideline on ED [5] designates oral PDE5 inhibitors as first-line pharmacotherapy. That guideline status gives sildenafil favorable formulary positioning.

Alprostadil coverage is more complex. Many insurers classify Caverject and MUSE as second-line and require a step-therapy protocol: the patient must have tried and failed (or demonstrated a contraindication to) at least one PDE5 inhibitor. Documentation requirements often include a letter from the prescribing urologist describing the clinical rationale. Some plans exclude injectable ED therapies entirely. Medicare Part D plans vary widely, with some covering alprostadil injection under specialty tiers (Tier 4 or 5) carrying 25 to 33% coinsurance.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and a lead author on the AUA erectile dysfunction guideline, has noted: "Intracavernosal injection remains the most effective non-surgical treatment for ED, yet access barriers, including cost and pharmacy stocking, prevent many eligible men from receiving it" [5].

Tricare covers both sildenafil and alprostadil but applies its own quantity limits. The VA formulary lists both drugs and generally provides them at lower copays ($5 to $11 per 30-day supply for preferred generics), making VA beneficiaries one of the few populations where the cost gap narrows substantially.

Pharmacy Availability and Distribution

Walk into any of the roughly 40,000 retail pharmacies in the United States and sildenafil will almost certainly be on the shelf. The same cannot be said for alprostadil, and this availability gap creates a friction point that discourages its use even when clinically appropriate.

Generic sildenafil tablets require no special storage. They ship at room temperature in standard bottles, carry long shelf lives (typically 24 to 36 months), and move in high volume. Every major pharmacy chain, independent pharmacy, mail-order service, and telehealth platform stocks them. Digital health companies (Hims, Ro, Lemonaid) have made sildenafil prescriptions available through asynchronous consultations with delivery in 2 to 5 days.

Alprostadil injection (Caverject) requires refrigeration at 2 to 8 degrees Celsius during storage, though the reconstituted form is stable at room temperature for up to 24 hours. MUSE pellets must be stored at 2 to 8 degrees Celsius and kept in their foil pouches until use. These cold-chain requirements mean that many retail pharmacies do not keep either product in regular inventory. Patients often face special-order wait times of 3 to 7 business days. Specialty pharmacies and compounding pharmacies are more reliable sources but may not be locally accessible.

The FDA's Approved Drug Products database (Orange Book) [4] lists multiple ANDA holders for alprostadil injection, yet market availability remains concentrated among a small number of distributors. Production economics explain part of this: injectable biologics and prostaglandins carry higher manufacturing costs and lower demand volume compared to oral tablets, compressing margins for generic manufacturers.

Mail-order specialty pharmacies (Optum Specialty, Accredo, CVS Specialty) provide the most consistent Caverject and MUSE supply, often with free overnight cold-pack shipping. Patients who rely on alprostadil long-term generally transition to a specialty pharmacy relationship after initial titration visits with their urologist.

Titration, Training, and Hidden Costs

The sticker price per dose does not capture the full cost of alprostadil therapy, which involves in-office titration sessions and self-injection training that sildenafil does not require. These ancillary costs further widen the economic gap between the two drugs.

Sildenafil prescribing is straightforward. A clinician writes a prescription, the patient fills it, and takes the tablet 30 to 60 minutes before sexual activity. No office-based training is needed. The initial visit (in-person or telehealth) and any follow-up to adjust dosing represent the only professional fees.

Alprostadil injection requires a different onboarding process. The AUA guideline recommends that intracavernosal injection therapy begin with in-office dose titration under direct supervision [5]. This typically involves 1 to 3 office visits during which the urologist or nurse practitioner injects escalating doses (starting at 2.5 mcg, titrating up in increments of 2.5 to 5 mcg) while monitoring for priapism and measuring erectile response with a rigidity assessment. Each office visit carries a copay and potentially a procedure code charge. After titration, the patient receives self-injection training with a practice injection under observation.

MUSE requires less intensive training but still involves an in-office test dose to confirm response and rule out hypotension or urethral pain. The first pellet is administered in the clinic with vital sign monitoring for 30 to 60 minutes.

Dr. Hossein Sadeghi-Nejad, Director of the Center for Male Reproductive Medicine at Hackensack University Medical Center, has stated: "The economics of injection therapy extend well beyond drug cost. When you factor in titration visits, training time, and the supplies needed for self-injection, the total first-year cost of intracavernosal therapy is three to five times what patients expect based on the per-dose price alone."

These hidden costs include alcohol swabs, 27- to 30-gauge needles (for Caverject), and sharps disposal containers. While individually inexpensive, they add $50 to $100 annually and require procurement planning that oral therapy avoids entirely.

When Alprostadil Makes Clinical and Economic Sense

Despite its higher cost and access complexity, alprostadil fills a specific clinical niche where sildenafil and other PDE5 inhibitors cannot perform. In these scenarios, the cost comparison shifts because the alternative is often a penile implant ($15,000 to $25,000 surgical cost) or no treatment at all.

Alprostadil becomes the preferred option in three clinical situations. First, men with contraindications to PDE5 inhibitors: patients taking nitrates (nitroglycerin, isosorbide mononitrate) for angina cannot safely use sildenafil due to the risk of severe hypotension. The FDA's sildenafil prescribing information [6] carries a black-box-level contraindication for concurrent nitrate use. For these men, alprostadil is safe because it acts locally without systemic vasodilation.

Second, men who have failed PDE5 inhibitors: the Linet trial population included men with vascular and neurogenic ED who had not responded to other treatments, and the roughly 70% response rate [2] in this difficult population established alprostadil as the standard second-line therapy. Post-radical-prostatectomy patients with cavernous nerve injury represent the largest subgroup in this category.

Third, men with severe vasculogenic ED and poor arterial inflow: PDE5 inhibitors require some baseline erectile capacity to work (they amplify existing nitric oxide signaling). When the vascular substrate is severely compromised, direct smooth-muscle relaxation via alprostadil bypasses this dependency.

In these populations, the cost comparison is not sildenafil vs alprostadil. It is alprostadil ($5,200 per year) vs penile prosthesis surgery ($15,000 to $25,000 upfront, with device revision rates of approximately 7 to 15% at 10 years [7]). Viewed through that lens, alprostadil is the cost-effective intermediate step.

Switching from Sildenafil to Alprostadil

The clinical pathway from oral PDE5 inhibitor failure to intracavernosal or intraurethral alprostadil is well-defined in the AUA guideline [5] and follows a logical step-therapy sequence. Patients do not need to fail all four available PDE5 inhibitors before switching.

A reasonable switching protocol looks like this: after an adequate trial of sildenafil (at least 4 to 6 attempts at the maximum tolerated dose, taken on an empty stomach, with appropriate sexual stimulation and timing), a patient who reports insufficient rigidity or no response can be transitioned. The prescribing clinician should document the PDE5 inhibitor trial duration, doses used, and reason for failure. This documentation serves both the clinical record and the insurance prior authorization for alprostadil.

Some clinicians offer a brief trial of a second PDE5 inhibitor (tadalafil 20 mg, for example) before moving to injectables, particularly because tadalafil's longer half-life (17.5 hours vs. sildenafil's 3 to 5 hours) suits men who prefer a wider activity window. If two PDE5 inhibitors have failed, further oral attempts rarely change the outcome. A prospective study of 219 men published in the Journal of Urology found that men who did not respond to two different PDE5 inhibitors had only a 4% chance of responding to a third [8].

The first alprostadil injection should occur in the office. Starting doses for Caverject range from 2.5 mcg (neurogenic ED) to 10 mcg (vasculogenic ED), titrated upward in 5 mcg increments until an erection lasting 30 to 60 minutes is achieved without priapism. The maintenance dose for most men falls between 10 and 20 mcg. Patients should not exceed 60 mcg per injection or inject more than 3 times per week, with at least 24 hours between doses.

Telehealth and Digital Access Pathways

Telehealth has widened the access gap between sildenafil and alprostadil. Oral PDE5 inhibitors are well-suited to asynchronous prescribing. Injection therapy is not.

Sildenafil is among the most commonly prescribed medications through telehealth platforms. Companies operating in this space have built entire business models around the low clinical complexity of PDE5 inhibitor prescribing: a structured intake questionnaire, asynchronous physician review, e-prescribing, and home delivery. The CDC reports that telehealth utilization for chronic condition management increased 154% during 2020 [9], and men's sexual health was one of the fastest-growing telehealth categories.

Alprostadil cannot be prescribed through asynchronous telehealth alone. The requirement for in-office titration and supervised first injection means a patient must see a urologist or trained clinician in person at least once, typically two to three times, before independent self-administration. While follow-up prescriptions can be managed via telehealth after the training period, the initial access barrier is physical presence in a clinic.

This creates a geographic access disparity. Men in rural areas with limited urology access may face drives of 60 miles or more for alprostadil titration, while sildenafil is available to anyone with an internet connection and a valid prescription. The American Urological Association has identified urology workforce shortages in rural counties, with 43% of U.S. counties lacking a single practicing urologist [10].

Compounding pharmacies have partially closed this gap by shipping trimix kits with telehealth-based prescribing, though this practice exists in a regulatory gray area that varies by state.